A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Afatinib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Carcinoma; Gallbladder cancer
- Focus Therapeutic Use
Most Recent Events
- 16 Oct 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 16 Oct 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.
- 21 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.